LONDON (Alliance News) - Sareum Holdings PLC said Wednesday it has been granted a patent for its kinase inhibitors by the Japanese patent office.
The patent covers compounds that inhibit or modulate kinase enzymes, which is the basis of its SKIL drug discovery platform. Sareum expects to receive similar patent protection in Europe and other major markets, it said.
"The granting of this patent in Japan strengthens our patent portfolio, and enhances our negotiating position with potential licensing partners," said Chief Scientific Officer John Reader in a statement.
Shares in Sareum were trading up 2.8% at 0.550 pence Wednesday morning, shortly after market open.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Sareum (SAR)